Prime Medicine, Inc.

NASDAQ:PRME

Biotechnology

Healthcare
$3.82 -1.11%

-$0.04 today

Market cap
$694.94M
Beta
2.31
P/E (TTM)
-2.8
EPS (TTM)
-$1.12
52W Low $1.77High $6.94

Volume 4.62M

Average 2.47M

PRME Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Prime Medicine, Inc.NASDAQ: PRME

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue dips below year-ago levels

Q1 FY2026 revenue of $856K fell 41.1% year over year, behind the +4.9% change in trailing-twelve-month revenue. Sequentially, it rose 2.1% from the prior quarter.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 8 analysts of $10.7M (+130.9%) for the fiscal year ending Dec 2026, a step up from the +55.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$856K+2.1% QoQ
Last fiscal yearDec 2025
$4.63M+55.3% YoY
LTMMar 2026
$4.03M+4.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-41.1%+101.9%+143.0 pp
1 year+55.3%+130.9%+75.6 pp
3-year CAGR—+74.5%—
5-year CAGR+87.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
4.63M USD
Year-over-year change
+55.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How PRME compares with its peers on the latest reported figures

  • PRME's LTM Mar 2026 revenue of $4.03M is the 6th highest of the 7 companies compared; the peer median is $31.93M.
  • Its year-over-year change of +4.9% is the 5th highest of 6, against a peer median of +13.0%.
PRME Competitors Peer median
Revenue for PRME and competitors
Company Period LTM YoY 3-year CAGR
BEAMBeam Therapeutics Inc.LTM Jun 2026$156.04M +158.9%+31.9%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$66.09M +45.0%+9.1%
EDITEditas Medicine, Inc.LTM Mar 2026$38.69M +8.0%+27.1%
CRSPCRISPR Therapeutics AGLTM Sep 2026$25.17M -33.1%+100.4%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.2M +13.0%-7.0%
PRMEPrime Medicine, Inc.LTM Mar 2026$4.03M +4.9%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$0 ——
SCTXScribe Therapeutics Inc.—— ——
Peer median (excluding PRME) $31.93M+13.0%+27.1%

Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0002.98M4.63M
Cost of Revenue00007.32M
Gross Profit0002.98M(2.69M)
Gross Margin———100.0%-58.1%
Research & Development70.55M86.73M147.91M155.29M160.64M
Selling, General & Admin13.92M29.82M43.39M50.16M52.35M
Operating Expenses84.47M116.54M204.79M205.45M205.66M
Depreciation & Amortization568K2.22M4.65M6.13M5.38M
EBITDA(165.29M)(120.55M)(186.64M)(189.75M)(195.76M)
EBITDA Margin———-6361.2%-4226.2%
Operating Income(84.47M)(116.54M)(204.79M)(202.47M)(208.35M)
Operating Margin———-6787.4%-4498.1%
Interest Income0003.52M4.15M
Interest Expense00000
Other Income / Expenses(81.38M)(6.23M)6.38M6.59M7.21M
Income Before Tax(165.85M)(122.77M)(198.41M)(195.88M)(201.14M)
Pre-Tax Margin———-6566.6%-4342.4%
Income Tax Expense(486K)(948K)(279K)00
Net Income(165.37M)(121.82M)(198.13M)(195.88M)(201.14M)
Net Margin———-6566.6%-4342.4%
EPS (Basic)(1.92)(1.46)(2.18)(1.65)(1.35)
EPS (Diluted)(1.92)(1.46)(2.18)(1.65)(1.35)
Weighted Avg Shares95.73M97.21M90.97M118.6M148.76M
Weighted Avg Shares (Diluted)95.73M97.21M90.97M118.6M148.76M

Prime Medicine, Inc.

NASDAQ:PRME

Intrinsic Alpha fair value

Locked

Current Price

$3.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.